<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>High-dose <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (Cy) has been promoted as curative therapy for severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA) </plain></SENT>
<SENT sid="1" pm="."><plain>However, our randomized trial comparing antithymocyte globulin (ATG) and Cy was terminated early because of excess morbidity/early mortality in the Cy arm </plain></SENT>
<SENT sid="2" pm="."><plain>We now report analysis of secondary endpoints at a median of 38 months </plain></SENT>
<SENT sid="3" pm="."><plain>Relapse occurred in 6 (46%) of 13 responders in the ATG arm versus 2 (25%) of 8 in the Cy arm (P =.38) </plain></SENT>
<SENT sid="4" pm="."><plain>Five (31%) of 16 patients in the ATG arm and 4 (27%) of 15 patients in the Cy arm had evidence of <z:hpo ids='HP_0004818'>paroxysmal nocturnal hemoglobinuria</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>) at diagnosis, with no substantial change in the overall percentage of glycophosphatidyl <z:chebi fb="1" ids="24848">inositol</z:chebi> (GPI)-anchored protein-deficient neutrophils over extended follow-up in individual patients in either arm </plain></SENT>
<SENT sid="5" pm="."><plain>Bone marrow cytogenetic abnormalities have been observed among surviving patients in both arms (2 of 14 ATG versus 1 of 12 Cy, P =.70) </plain></SENT>
<SENT sid="6" pm="."><plain>High-dose Cy does not prevent relapse or <z:e sem="disease" ids="C1516669" disease_type="Neoplastic Process" abbrv="">clonal evolution</z:e> in SAA </plain></SENT>
</text></document>